Shiraya Tomoyasu, Kato Satoshi, Shigeeda Takashi
Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Int Ophthalmol. 2014 Oct;34(5):1115-7. doi: 10.1007/s10792-013-9802-y. Epub 2013 Jun 1.
To determine the optimal area of retinal photocoagulation required for suppressing active neovascularisation (NVI) associated with diabetic retinopathy. We studied 1 eye each of 4 patients in whom active NVI was ophthalmoscopically shown to have been suppressed by additional photocoagulation. These patients initially underwent pan-retinal photocoagulation for diabetic retinopathy at another hospital, but NVI developed subsequently. We compared the areas of photocoagulation before and after additional photocoagulation and compared the area of retinal photocoagulation. The photocoagulated areas before and after additional photocoagulation in the four eyes were 20.7 and 45.2, 36.6 and 56.3, 30.4 and 67.4, and 11.7 and 53.4 %, respectively. The area of retinal photocoagulation required to suppress active NVI is calculated to be ~50 %.
为确定抑制与糖尿病性视网膜病变相关的活动性新生血管形成（NVI）所需的视网膜光凝最佳面积。我们研究了4例患者的各1只眼，这些患者经眼底镜检查显示，额外的光凝已抑制了活动性NVI。这些患者最初在另一家医院接受了糖尿病性视网膜病变的全视网膜光凝，但随后出现了NVI。我们比较了额外光凝前后的光凝面积，并比较了视网膜光凝面积。4只眼中额外光凝前后的光凝面积分别为20.7%和45.2%、36.6%和56.3%、30.4%和67.4%、11.7%和53.4%。据计算，抑制活动性NVI所需的视网膜光凝面积约为50%。
